Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
Michael Friedländer(Prince of Wales Hospital), Paul DiSilvestro(Women & Infants Hospital of Rhode Island), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), C. Gourley(Edinburgh Cancer Research), Alexandra Léary(Institut Gustave Roussy), Giovanni Scambia(Agostino Gemelli University Polyclinic), N. Colombo(European Institute of Oncology), Gabe S. Sonke(Oncode Institute), C. Aghajanian(Memorial Sloan Kettering Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Amit M. Oza(Ontario Institute for Cancer Research), Ralph Bloomfield(Takeda (United States)), Anne Floquet(Institut Bergonié), E.S. Lowe(AstraZeneca (United States)), B.-G. Kim(Samsung Medical Center), K.N. Moore(Oklahoma State University Oklahoma City), W.H. Bradley(Froedtert Hospital), Alla Lisyanskaya(City Clinical Oncology Center)
Cited by 2
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k